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Only 1.2 kilobases (kb) at the 5' end of the 3.9-kb v-abl sequence in Abelson murine leukemia virus is
required for fibroblast transformation. A precise delineation of this minimum transforming region was made
by using small 5' or 3' deletions. Insertions of four amino acids, generated by putting synthetic DNA linkers
into various restriction enzyme cleavage sites, abolished transforming activity, indicating that much of the
internal sequence of the minimum transforming region plays a critical role in the transformation process. This
5' 1.2 kb of v-abl encodes protein-tyrosine kinase activity when expressed in Escherichia coli. Each of the
mutations which caused a loss of transformation activity also resulted in a loss of protein-tyrosine kinase
activity when expressed in E. coli. The minimum transforming region of v-abl contains amino acid homology
to other protein-tyrosine kinase oncogenes, and a comparison with these oncogenes is presented.
Abelson murine leukemia virus (A-MuLV) is a replication-
defective retrovirus capable of transforming fibroblast cells
in vitro (28) and lymphoid cells both in vitro and in vivo (1,
25, 26). The viral genome encodes a single protein, the gene
for which was produced as a result of a fusion between the
Moloney MuLV (M-MuLV) gag gene and cell-derived v-abl
sequences (11, 24, 32, 38, 44). The largest variant of A-
MuLV encodes a 160-kilodalton (kd) protein, of which 130
kd is determined by the v-abl sequence, but only the
N-terminal 45 kd of the v-abl-encoded protein sequence is
required for fibroblast transformation (22). Though nearly all
of the gag sequence can be deleted without abolishing
fibroblast transformation, much of gag is essential for lym-
phoid transformation (22).
The v-abl gene, along with src and several other onco-
genes, encode proteins that display tyrosine-specific protein
kinase activity (13, 41). In addition, these various oncogene
products have a region of strongly conserved amino acid
sequence (3, 23, 31). In the v-abl-encoded protein, this
homology region resides within the N-terminal 45 kd, a
segment we will refer to as the minimum transforming
region. J. J.-Y. Wang and D. Baltimore (J. Biol. Chem., in
press) expressed this region in E. coli and found that its
product displays protein-tyrosine kinase activity, demon-
strating that the protein-tyrosine kinase domain and mini-
mum transforming region are contained within the same
1.2-kilobase (kb) fragment of v-abl sequence. Witte et al.
(42) showed that a transformation-defective mutant, A-
MuLV[P92tdJ, contains a deletion within this region and
lacks tyrosine-specific in vitro autophosphorylation activity.
Srinivasan et al. (34) also tested plasmids cut within this
region and found them to be transformation defective.
We have now further tested the requirement for the
minimum transforming region by constructing specific mu-
tants. Small 5' or 3' deletions were made to examine the
outer boundaries. Insertions of four amino acids at various
points were made to test for the necessity of internal
sequences. We found that nearly all the mutations within the
minimum transforming region result in transformation-defec-
tive genomes. The mutant genes were expressed in Esche-
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richia coli and assayed for protein-tyrosine kinase activity.
The loss of transforming ability correlated with a loss of
tyrosine-specific protein kinase activity.
MATERIALS AND METHODS
Cells and viruses. Normal and A-MuLV-transformed
NIH/3T3 fibroblasts were grown in Dulbecco modified
Eagle's medium with 10% calf serum. Transfections by the
calcium phosphate method were performed essentially as
described (40) and modified (22).
Bacterial labeling. [35SJmethionine metabolic labeling and
32p; in vivo pulse-labeling of E. coli HB101 containing the
various expression plasmids were performed essentially as
described (39). For [35S]methionine labeling, bacteria were
grown in minimal medium containing all the amino acids
except methionine. An overnight culture was diluted 1:40
into fresh methionine-free medium and incubated for 2 h at
30°C. The culture was then shifted to 40°C for 1 h.
[35S]methionine was then added to 100 ,uCi/ml, and the
bacteria were incubated for 1 h at 40°C. The bacteria were
then collected by centrifugation and resuspended in 0.5 ml of
phospholysis buffer (10 mM sodium phosphate [pH 7.5], 100
mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1%
sodium dodecyl sulfate [SDS], and 2 mM EDTA). The
sample was sonicated twice for 15 s and centrifuged at
13,000 x g for 15 min. Three microliters of anti-AbT serum
(a mouse serum from an animal that had rejected an A-MuLV-
induced tumor [43]) was added to the supernatant and
incubated on ice for 1 h. Twenty-five microliters of a 50%
protein A-Sepharose suspension was then added and incu-
bated on ice for 30 min. The immune complexes were
collected by centrifugation and washed four times in phospho-
lysis buffer and two times in water. The complexes were
then resuspended in 50 ,ul of SDS buffer (67 mM Tris-hydro-
chloride [pH 6.8], 2% SDS, 10% glycerol, 5 mM EDTA, 20
mM dithiothreitol, and bromophenol blue). This solution
was boiled for 5 min and fractionated by electrophoresis
through an SDS-10% polyacrylamide gel as described else-
where (44). Samnples were normalized for trichloroacetic
acid-precipitable radioactivity before immunoprecipitation.
The final gel was treated with En3Hance (New England
Nuclear Corp.) and developed by fluorography.
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For in vivo labeling of E. coli with 32P042-, bacteria were
grown overnight at 30°C in L broth. This culture was diluted
1:40 into fresh medium, grown to mid-log phase (A650 = 0.3)
at 30°C, and shifted to 40°C for 2 h. Samples were then
normalized for cell number, collected by centrifugation, and
washed twice in 50 mM Tris-hydrochloride (pH 7.5)-100 mM
NaCI-10 mM MgCI2. The bacteria were then resuspended in
the same buffer at 3 x 109 cells per ml (A650 = 0.1 = 8 x 107
cells per ml). These steps were all performed at 4°C. Five
microliters of 300 ,uCi of 32P042- per ml was added to 45 ,ul
of the above bacterial suspension and incubated at 40°C for
15 min. Twenty five microliters of 3 x SDS buffer was added,
and the bacteria were lysed by boiling for 10 min. Twenty-
five microliters was then electrophoresed through an
SDS-10% polyacrylamide gel. The gel was fixed in 20%
isopropanol-10% acetic acid for longer than 30 min and then
soaked in 1 N NaOH at 50°C for 1 h. This gel was washed
twice quickly with water and soaked in 10% acetic acid for
longer than 30 min. Finally the gel was dried down and
developed by autoradiography with an intensifying screen.
Plasmid construction. (i) pRl. The circularly permuted
P160 coding plasmid, pAB160 (17), was modified to remove
the EcoRI site in the pBR322 backbone. This was done by
the following scheme: (i) digesting with EcoRI, (ii) filling in
the cohesive ends with the Klenow fragment of E. coli
polymerase I, (iii) blunt-end ligating to recircularize, (iv)
digesting with excess EcoRI to select against plasmids still
retaining an EcoRI site, (v) transforming E. coli to ampicillin
resistance, and (vi) screening colonies for intact plasmids
lacking the EcoRI site. DNA was prepared rapidly from the
colonies by the method of Ish-Horowicz and Burke (15) and
digested with the appropriate diagnostic restriction en-
zymes.
The plasmid pRl was formed by inserting 12 base pairs
(bp) at the first HinclI site in the v-abl region of an
EcoRI-less plasmid. The 12-bp unit was a synthetic piece of
DNA containing an EcoRI site; we will refer to this unit as
an (EcoRI)linker. Because there are four HinclI sites in the
plasmid, (EcoRI)linkers were placed randomly, and the
appropriate plasmid was selected by screening their struc-
tures. To this end the plasmid was partially digested with
HinclI, producing blunt ends, and linear DNA was isolated
from an agarose gel by using glass powder (37).
(EcoRI)linkers were ligated to this DNA overnight at 15°C.
The sample was then phenol extracted once, ether extracted
twice, and ethanol precipitated. The DNA was digested with
EcoRI to remove excess linkers and again phenol and ether
extracted and ethanol precipitated. This DNA was ligated to
recircularize it and used to transform E. coli to ampicillin
resistance. Colonies were screened for intact plasmids con-
taining the linker in the desired position.
(ii) pBl. pRl was used to generate pBl. pRl, with an
(EcoRI)linker at what was formerly the first HincII site of
v-abl, was digested with EcoRI. After phenol and ether
extraction and ethanol precipitation, the DNA was treated
with Bal 31 exonuclease and titrated to remove ca. 100 bp
from each end. The reaction was terminated with 50 mM
EDTA, phenol and ether extracted, and ethanol precipi-
tated. The DNA was then treated with the Klenow fragment
of E. coli DNA polymerase I to blunt any single-stranded
ends. (EcoRI)linkers were then ligated on. After further
extractions and ethanol precipitations, the DNA was di-
gested with EcoRI, and full-length DNA was electrophoreti-
cally purified away from excess linkers. This DNA was
ligated to recircularize it and used to transform E. coli to
ampicillin resistance. The colonies were screened for small
deletions around the HinclI site. pBl was sequenced on both
strands by the method of Maxam and Gilbert (19) and found
to contain an in-frame deletion of 231 bp, removing the last
49 amino acids of gag and the first 28 amino acids of v-abl
and leaving at the junction four amino acids encoded by the
linker (Pro-Glu-Phe-Gly).
(iii) pABS. pABS was derived from a proviral P160-
encoding clone, pABpv (22). pABpv was partially digested
with Sacl, and single-cut linear DNA was electrophoretic-
ally purified. This DNA was treated with the Klenow frag-
ment to remove the cohesive ends. The enzyme was heat
killed at 68°C for 10 min. The DNA was blunt-end ligated to
recircularize it and used to transform E. coli to ampicillin
resistance. The colonies were screened for intact plasmids
lacking the particular Sacl site of interest due to the removal
of the 4-bp cohesive ends. This puts the coding region out of
frame at this point.
(iv) pPs. pPS was made similarly to pAB-p (22). A retro-
viral vector, pMSVgpt (20), was used. Once the gpt gene
was removed, a BglII site was left where the first PstI site of
M-MuLV was. The analogous PstI site of A-MuLV was
used. To prepare pPS, a PstI-to-SacI fragment was elec-
trophoretically purified. The cohesive ends were removed
with the Klenow fragment of DNA polymerase I, and 12-bp
(BamHI)linkers were ligated on. pMSVgpt was digested with
BglII and treated with calf intestinal phosphatase. The BglII
fragment (the entire plasmid without the gpt gene) was gel
purified and ligated to the A-MuLV fragment described
above (BamHI and BglII have compatible cohesive ends).
Ampicillin-resistant colonies were screened for the insert in
the correct orientation.
(v) Linker DNA insertions. Either pAB160 (lacking an
EcoRI site as described above) or pABX was used for
insertion of 12-bp DNA segments. pABX codes for a 100-kd
transforming Abelson protein (22; see Fig. 1). The plasmids
were digested partially with restriction enzyme HaeIII and
fractionated by electrophoresis through an agarose gel to
isolate singly cut, linear DNA. Linker DNA was ligated onto
this linear DNA overnight at 15°C. (EcoRI)linkers 12 bp in
length were used for pAB160; 12-bp (BamHI)linkers were
used for pABX. After ligation of the linkers, the DNA was
phenol and ether extracted and ethanol precipitated. Excess
linkers were subsequently removed by digestion with the
appropriate restriction enzyme and fractionation by elec-
trophoresis through an agarose gel. Linear DNA was puri-
fied from the gel, ligated to close the circles, and used to
transform E. coli to ampicillin resistance. Colonies were
screened for linker restriction sites within the minimum
transforming region. The names of the plasmids generated
and the position of the linker insertions are listed below (see
Fig. 2).
(vi) ptX. ptX was generated from pt(b)abll30, kindly
provided by Jean Wang. She placed a unique BamHI site
within the small t region of the fusion protein encoded by
ptabll30 (Wang and Baltimore, in press). This plasmid was
further modified to remove the EcoRI site of pBR322 in the
same way as described above. To change the BamHI site to
an EcoRI site, the resultant plasmid was digested with
BamHI and treated with the Klenow fragment, and
(EcoRI)linkers were ligated on. After extractions and ethanol
precipitation the DNA was digested with EcoRI and SalI. A
fragment containing EcoRI and SalI cohesive ends was
electrophoretically purified, the EcoRI site then being where
the BamHI site was in pt(b)abll30, leaving 58 amino acids of
simian virus 40 small t coding sequence. The Sall site is in
pBR322. An EcoRI-to-XhoI fragment was purified from pRl,
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FIG. 1. Genomes used to delineate the extent of the minimum transforming region. The structure of different A-MuLV genomes are
shown, along with the names of the corresponding plasmids and their ability to transform NIH/3T3 cells upon transfection with helper virus
(M-MuLV) DNA. The protein products are indicated with wavy lines, along with certain relevant restriction sites. Gaps denote deletion of
these sequences in the corresponding plasmid. X, The Sad site in.pABS was destroyed by removal of the 4-bp cohesive ends, putting the
coding region out of frame at this point.
the EcoRI site being where the first HinclI site of v-abl was
(see above). This fragment corresponds to the 5' 1.8 kb of
v-abl. The two fragments described above were ligated
together (XhoI and Sall have compatible cohesive ends) and
used to transform E. coli to ampicillin resistance. The
resultant plasmid is diagrammed below (see Fig. 4).
(vii) ptBl. ptBl was made exactly as above, except that
pBl was used instead of pRl.
(viii) ptXB1, ptXB3, ptXB4, ptXB5. ptXB1, ptXB3, ptXB4,
and ptXB5 were generated as above, except that pXB1,
pXB3, pXB4, or pXB5 was used instead of pRl. These
plasmids were digested with HincII, and (EcoRI)linkers
were ligated on at this site. The DNA was subsequently
digested with EcoRI and XhoI and electrophoretically puri-
fied to generate a fragment similar to that described above,
except for the linker insertion mutation in each of the
plasmids.
(ix) ptHl. pt(b)abll3O was digested with BamHI and XhoI
to generate the backbone fragment. pHi was digested with
HincII, and 10-bp (BamHI)linkers were ligated on at this
point. The DNA was digested with BamHI and XhoI to
generate a fragment similar to those above, yet containing
the EcoRI linker insertion present in pHi. These two gel
purified DNAs were ligated together to make ptHl.
All the plasmids described under subheads vi through ix
were constructed to retain the coding region of the small
t-v-abl fusion protein in frame.
All restriction enzymes and Bal 31 exonuclease were
obtained from New England Biolabs except for EcoRI.
EcoRI, calf intestinal phosphatase, and the Klenow fragment
of E. coli DNA polymerase I were from Boehringer Mann-
heim Biochemicals. Linker DNA and T4 DNA ligase was
obtained from Collaborative Research, Inc.
RESULTS
Delineation of the minimum transforming region. We have
previously shown that the 5' 1.2 kb of v-abl, when expressed
as a fusion protein with the N-terminal 34 amino acids of gag
(plasmid pAB-P; Fig. 1), is sufficient for fibroblast transfor-
mation by A-MuLV (22). To further define the limits of this
region we made small deletions at the 5' and 3' ends and
tested the ability of these plasmids to transform NIH/3T3
cells.
For the 5' deletions we used Bal 31 exonuclease to
generate a small deletion in a P160-coding clone (see above
for details of construction). This plasmid, pBl (Fig. 1), was
sequenced across the deletion site and was found to contain
an in-frame deletion that removed the first 28 amino acids of
v-abl, as well as the last 49 amino acids of gag. This region
of gag is not required for fibroblast transformation (22).
Plasmid pBl did not cause transformed foci when transfec-
ted onto NIH/3T3 cells along with helper virus DNA. The
helper virus DNA greatly increases the efficiency of focus
formation after transfection with A-MuLV DNA (11, 12).
Use of the helper means that foci are formed by spread of
virus from the initially transfected cell. Thus, even this small
5' deletion removes sequence required for transformation.
At the 3' end, a termination mutation was made at the
SacI site 159 bp 5' of the PstI site used to make the
transforming plasmid, pAB-P (Fig. 1). The mutated plasmid,
pABS, had its Sacl site destroyed by blunting the cohesive
ends (see above for details). This resulted in putting the
coding region out of frame at this point. A similar plasmid,
pPS, was constructed which had only the sequence up to the
Sacl site (see above). Neither pABS nor pPS transformed
NIH/3T3 cells upon transfection with helper virus DNA.
The 3' end of the minimum transforming region is therefore
between the PstI and Sacl sites.
Linker insertion mutations in v-abl. To probe which parts
of the internal sequence in the minimum transforming region
of v-abl might be dispensable, we constructed a series of
mutant plasmids containing 12-bp insertions within this
region. These insert four amino acids while retaining the
coding region in frame. The mutations were generated by
partial digestion of plasmids with the restriction enzyme
HaeIII to generate linear DNA. HaeIII recognizes 10 sites
within the minimum transforming region, so that a partial
digest generating linear DNA should result in the random
cleavage at one of these sites. Linear DNA was purified from
agarose gels, and 12-bp units containing restriction en-
zyme cleavage sites (linkers) were ligated onto this DNA.
The mutations were generated in two sets by utilizing either
plasmid pAB160 or pABX. For pAB160, 12-bp (EcoRI)
linkers were used; for pABX, 12-bp (BamHI)linkers were
used. In the final step, the DNA was ligated to close the
circles and used to transform E. coli to ampicillin resistance
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FIG. 2. Position of linker insertions. The coding region of the
A-MuLV protein is diagrammed. The positions of (EcoRI) or
(BamHI)linker insertions in particular mutant plasmids are indi-
cated. The PstI restriction site marks the 3' boundary of the
minimum transforming region. The amino acid number positions of
P160 are indicated by using 1 through 236 for the gag section of the
protein, followed by 1 through 1008 for v-abl.
(see above for more details). Because HaeIII digestion
leaves blunt ends, the above process resulted in insertion of
only the 12-bp linker unit. We sequenced across each of the
linker insertion mutation sites to confirm their position and
sequence. As expected, all mutants contained the 12-bp
linker DNA insertion within an HaeIII site. In all cases the
coding region remained in frame.
The plasmids generated and the position of their linker
insertions are indicated in Fig. 2. In a separate construction
an (EcoRI)linker was inserted at the HincIl site near the
beginning of v-abl to produce pRl. The mutant plasmids
were transfected, along with helper virus DNA, into NIH/3T3
cells. The plasmids were easily scored to be either as
transforming as their parental plasmids (100 to 500 foci per
,ug of DNA) or nontransforming (no foci) (Table 1). The one
exception was plasmid pH2 [containing an (EcoRI)linker
insertion], which had a 5- to 10-fold-lower transfection
efficiency than the parental pAB160. As a rule, insertions
near the 5' end had no effect; insertions within the minimum
transforming region abolished transforming activity.
Transformed foci were picked from the plates transformed
by plasmids pH4, pH3, and pH2 [all derived from pAB160
and containing an (EcoRI)linker]. Each of these lines ex-
pressed the expected 160-kd Abelson protein as detected by
in vitro autophosphorylation reactions in immunoprecipi-
tates (data not shown). Cellular DNA was made from these
lines and probed for the mutant viral genomes. As expected,
pH4- and pH3-transformed lines contained full-length viral
genomes, as well as the EcoRI site in the expected position
(data not shown). Three independent pH2-transformed lines
TABLE 1. Transformation by mutant plasmidsa
Plasmid Derivation Linker Insertion after Transformation
of plasmid inserted amino acid no.: cells
pH3 pAB160 EcoRI 228 of gag +
pRl pAB160 EcoRI 4 of v-abl +
pH4 pAB160 EcoRI 15 of v-abl +
pXB8 pABX BamHI 15 of v-abl +
pH2 pAB160 EcoRI 136 of v-abl + b
pXB5 pABX BamHI 136 of v-abl -
pXB4 pABX BamHI 154 of v-abl -
pXB3 pABX BamHI 229 of v-abl -
pXB1 pABX BamHI 268 of v-abl -
pHl pAB160 EcoRI 297 of v-abl -
a Linkers were 12 bp in size. The plasmids were cotransfected with M-
MuLV DNA. +, Transfection efficiency was comparable to that of the wild
type (100 to 500 foci per ,ug of DNA); -, no foci were observed.
b The transfection efficiency for pH2 was lower, ca. 50 foci per p.g of DNA.
contained full-length viral genomes; the predominant form in
each, however, did not contain the expected linker EcoRI
site. Two did contain a minor species corresponding to a
viral genome with a linker insertion. After cells were passed
for 1 month, DNA was again made from these two lines, and
they were found to have lost even this minor species: only
full-length proviruses which were insensitie to digestion
with EcoRI were present. This mutated plasmid apparently
has a weak transforming activity, but growth of transformed
cells into mass cultures selects for variants which have
altered the linker restriction sites. In another mutant, pXB5,
a (BamHI)linker had been inserted at exactly the same place
as the (EcoRI)linker in pH2. pXB was totally transformation
defective, presumably because different amino acids are
encoded by the two linkers. Thus, this site is clearly within
a region important for transformation (Fig. 2).
Mutations abolish tyrosine kinase activity. The only known
biochemical activity of the A-MuLV gene product is its
tyrosine-specific protein kinase activity. We were interested
in determining the effects of the mutations on this activity
and whether this correlated with the transforming abilities.
The mutants which are defective for transformation, how-
ever, gave no phenotype when transfected into NIH/3T3
cells. In one approach to recovering cells that might express
the transformation-defective proteins, we cotransfected the
mutant plasmids with a construct, pSV2gpt, containing a
selectable gene. Although we were able to isolate cell lines
containing the mutant genomes, these cell lines were not
useful for biochemical analysis of the proteins. We could
detect some expression of each of the defective proteins, but
their levels were low when compared with transforming
proteins in infected cells. In addition, with time in culture
the cell lines lost even the low level of defective protein they
had synthesized. We attribute these problems to differences
in expression and stability of genes in transfected versus
infected cells (14). As an alternative approach we chose to
vz-cl
t (SV40)
tEcoR!-" (HinclI)
ptX orBamH[
AmpR P
(Xhol)
FIG. 3. v-abl bacterial expression vector. A map of the bacterial
expression plasmid, ptX, is shown. The sites of b-abl used for
insertion are indicated in parentheses and have been altered. An
EcoRI site is now where the HinclI site of v-abl was (a BamHl site
has been placed there in an alternative form of the plasmid used to
generate ptHl). The plasmid also contains 58 amino acids of simian
virus 40 small t coding sequence fused to v-abl. The lambda phage
PR promoter is used and a temperature-sensitive lambda phage cl
gene (ts-cI) is also on the plasmid, making expression from the PR
promoter inducible at a high temperature.
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analyze the effects of the mutations on v-abl proteins ex-
pressed in E. coli. Wang et al. (39) have shown that the v-abl
protein expressed in E. coli contains protein-tyrosine kinase
activity. The minimum transforming region described above
is sufficient to encode this activity (Wang and Baltimore, in
press). A mutant protein expressed from v-abl coding se-
quence only up to the Sacl site displays no protein-tyrosine
kinase activity (Wang and Baltimore, in press) correlating
with the inability of the equivalent mutant, pABS, to trans-
form cells.
To determine the effect of our various mutations on the
protein-tyrosine kinase activity of the protein made in E.
coli, we used an expression vector employed in earlier
studies (39). It was constructed to use the lambda phage PR
promoter and is heat inducible because of the inclusion in
the plasmid of a temperature-sensitive cI repressor gene
(Fig. 3) (39). To enhance production, v-abl is expressed in
the construct as a fusion gene with the first 58 amino acids of
simian virus 40 small t antigen (Wang and Baltimore, in
press). The 5' 1.2 kb, from HincII to XhoI, of the various
mutants of v-abl was expressed (see above for details of
construction). Each of the mutant clones resulted in the
expression of v-abl-specific proteins in E. coli. To estimate
the steady-state level of v-abl product, log-phase cells grown
at 30°C were shifted to 40°C for 1 h and then labeled for 1 h
at 40°C with [35S]methionine. Bacterial cell lysates were then
92- 4M
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FIG. 5. In vivo 32PO42- pulse-label of E. coli. Bacteria contain-
ing the different v-abl expression plasmids were induced for 2 h at
40°C and labeled for 15 min with 32p,. The cells were extracted and
analyzed by SDS-10% polyacrylamide electrophoresis as described
in the text. The gel was soaked in 1 N NaOH for 1 h to enrich for the
phosphotyrosine-specific signal and developed by autoradiography
(7, 8). The plasmid in each bacterial sample is indicated above each
lane. The positions of protein markers of known molecular mass (in
kd) are marked.
*_ ,72 Kdl- W
-5 5
-;
1 2 3 1 2 3 4 5 6 7
FIG. 4. [35S]methionine labeling of E. coli. Bacteria containing
the v-abl expression vector were labeled for 1 h with [35S]methionine,
extracted, immunoprecipitated with anti-AbT serum, and analyzed
by SDS-10% polyacrylamide electrophoresis as described in the
text. The plasmid present in each sample of labeled bacteria is
indicated above each lane. pCQV2 is the parent of ptX but contains
no v-abl insert. Plasmid ptX contains a wild-type fragment of v-abl,
whereas the other plasmids contain fragments harboring linker
insertions or in the case of ptBl, a deletion of the first 28 amino acids
of v-abl. These plasmids contain mutations corresponding to those
in the viral mutant plasmids; e.g., ptBl has the same mutation as in
pBl. The positions of proteins referred to in the text are indicated in
the center of the figure, whereas protein markers of known molec-
ular mass (in kd) are indicated on the outer borders. Panels (A) and
(B) represent two separate experiments.
immunoprecipitated with anti-AbT, a serum specific for
v-abl (43). Bacteria containing only the vector, pCQV2, had
some nonspecific proteins that immunoprecipitated (Fig. 4A,
lane 3); a plasmid encoding a wild-type v-abl protein ex-
pressed two specific proteins of 55 and 52 kd (lane 1) (Wang
and Baltimore, in press). Also evident was a greatly in-
creased amount of a 72-kd E. coli protein (Wang and
Baltimore, in press). All of the mutants tested produced
easily detectable amounts of abl-related proteins (Fig. 4A,
lane 2, and Fig. 4B).
To compare the tyrosine-specific kinase activities of the
proteins made in E. coli at 40°C, we labeled the bacteria with
32P042- and examined lysates for alkali-resistant phospho-
proteins (39). The wild-type v-abl product phosphorylates
itself and other bacterial proteins on tyrosine when bacteria
are labeled in this manner (39), and as expected, the wild-
type plasmid, ptX, caused phosphorylation of a number of
bacterial proteins (Fig. 5, lane 1). All but one of the other
plasmids were indistinguishable from the negative control,
pCQV2, containing no insert (lane 8). Thus, it appears that
each of the transformation-defective mutations within the
minimum transforming region resulted in a loss of kinase
activity as assayed in E. coli. There may be some phosphor-
ylation activity in the v-abl product of the 5' deletion
mutant, plasmid ptBl (lane 7), but it too is very strongly
reduced. These results demonstrate that the minimum trans-
forming region overlaps strongly with the kinase domain of
the protein. Although it is likely that the loss of kinase
activity demonstrated here is a reason for the loss of
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transforming ability, it is also possible that these proteins are
defective for other reasons, such as protein instability or loss
of other unknown activities.
DISCUSSION
The mutants described in this paper demonstrate the
importance of the 5' 1.2 kb of v-abl sequence for transfor-
mnation of NIH/3T3 cells by A-MuLV. This minimum trans-
forming region is sufficient for transformation when ex-
pressed as a fusion protein with gag or with only the first 34
amino acids of gag (22). Small 5' or 3' deletions into this
region, as well as four amino acid insertions, produced
transformation-defective viruses. The effect on protein-tyros-
ine kinase activity of these mutations was assayed, and in
each case mutations which caused a loss of transforming
activity also caused a loss of kinase activity.
Mutations within the minimum transforming region. The
5'- and 3'-end deletions described here both caused a com-
plete transformation deficiency, indicating that the N-termi-
nal border of the minimum transforming region lies between
amino acids 5 and 28, whereas the C-terminal border is
between amino acids 356 and 408. The linker insertions
demonstrate the requirement for much of the internal se-
quence of this region. Linker insertions near the 5' end had
no effect, but five of six internal insertions caused a total loss
of the ability to induce transformation. The sixth, pH2, was
also defective in that it had a lowered transfection efficiency
and its (EcoRI)linker sequence was lost upon passage of the
cells. In addition, a genome with a (BamHI)linker inserted at
the same position was totally transformation defective.
Correlation of kinase activity and the minimum transform-
ing region. As a measure of kinase activity, we expressed
v-abl in E. coli and assayed for incorporation of alkali-re-
sistant phosphate into protein. Each of the transformation-
defective linker insertion mutants had lost kinase activity by
this assay. The N-terminal deletion of 28 amino acids (in
plasmid pB1) had a severely reduced activity. Wang and
Baltimore found that a C-terminal deletion from the Sac! site
also caused a loss of tyrosine kinase activity (in press).
The correlation of kinase activity and transformation
ability demonstrated here strengthens the belief that the
kinase activity is responsible for the transforming activity of
the A-MuLV. Such experiments, however, cannot unambig-
uously demonstrate that kinase activity is necessary for
transformation because we cannot be sure that another
defect of unknown nature might not accompany the loss of
kinase activity. Our inability to recover cells stably express-
ing the mutant protein even leaves open the possibility that
instability of the protein due to intracellular proteases might
correlate with loss of kinase activity. Because the linker
insertion mutations are small and discrete, we doubt that all
of them would induce major changes in the folding of the
protein. The appearance of the same two bands of stable
v-abl-encoded protein in E. coli argues that the mutations do
not drastically disrupt the structure of the protein because
otherwise it would be degraded in E. coli. In fact, the
stability of the protein encoded by the minimum transform-
ing region is striking-the rest of the v-abl-encoded se-
quence is cleaved off and degraded rapidly in E. coli (39;
Wang and Baltimore, in press).
Minimum transforming region of three oncogenes encoding
a kinase. The studies reported here complement work from
other laboratories on mutants of viruses that encode tyros-
ine-specific protein kinases. In Fig. 6, we show the location
of our mutations along with others. For this purpose we have
aligned three amino acid sequences, those of v-abl (23; R.
Lee and D. Baltimore, unpublished data), v-src (30, 36), and
v-fps (31) (the alignment was by L. Shiman and D. Baltimore
[unpublished data]). The extensive amino acid homology of
these and other protein-tyrosine kinases has been widely
noted (3, 23, 31). Certain landmarks are evident, including
the tyrosine phosphorylated in vivo on pp6Ov-src (30, 36) and
the lysine that was affinity labeled by ATP in the cAMP-de-
pendent protein kinase (2, 33) (both marked by asterisks in
Fig. 6).
The sequence in Fig. 6 is limited to the region encompass-
ing the v-abl minimum transforming region. This was defined
previously for v-abl by deletions to begin no earlier than
amino acid 5 and to end before the PstI site at amino acid 408
(22). These limits can be slightly refined. (For this discussion
we will refer to amino acid numbers in the v-abl sequence,
but the equivalent numbers for v-src and v-fps can be
interpreted from Fig. 6.) Three insertions before amino acid
15 had no effect on transforming efficiency, suggesting that
the region up to this position is not required for transforma-
tion. The deletion in pBl abolishes transformation, how-
ever, indicating that the minimum transforming region be-
gins between amino acid 15 and 28 in v-abl. In v-fps, an
insertion of three amino acids at amino acid 13 (Tyr)
abolishes transformation (35), suggesting that its minimum
transforming region may also begin near this position. There
is also conserved homology here among the oncogenes,
suggesting an important function. For v-src, however, a
deletion up to amino acid 14 did not ablate transformation of
chicken embryo fibroblasts. Deletion to amino acid 31,
however, virtually abolished v-src transformation (F. Cross
and H. Hanafusa, personal communication), suggesting that
the minimum transforming region of v-src has its 5' end near
that of v-abl. Surprisingly, though, deletion of amino acids
34 to 85 in v-src gives only a temperature-sensitive transfor-
mation defect (5), implying that, at least at the permissive
temperature, this region is not needed for transformation.
The 3' end of the minimum transformation region is
probably best defined by examining the amino acid homol-
ogy of the three proteins. This homology extends to amino
acid 377, with the v-src and v-fps genes ending soon there-
after. A v-src deletion from amino acid 366 onward is
transformation defective (21). For v-abl, some sequence
beyond the Sacl site at amino acid 356 is needed, but
truncation at amino acid 408 (the PstI site) leaves transform-
ing activity. Thus, the data on the mutations are consistent
with a need for the entire region of homologous sequence
near the 3' end. In v-abl, 631 C-terminal amino acids follow
position 377. There is no absolute requirement for this large
C-terminal region of the protein, but transformation of
lymphoid cells, which may be a more stringent test than
transformation of fibroblasts, is more efficient when this
region is left intact (22a, 27).
Internal mutations within the v-abl minimum transforming
region all either abolished or greatly affected transformation.
This indicates that much of the region is required, but large
segments were not probed. Earlier, the P92 transformation-
defective deletion was isolated, which removed the whole
central area of the minimum transforming region (11, 42).
(We have since found that it arose from a deletion which
joined two in-phase 9-bp repeated sequences encoding the
amino acids Met-Glu-Arg; see Fig. 6.) Insertion mutants of
Ser-Arg-Glu in the place of Tyr residues in the v-fps gene
have also shown that much of the C-terminal portion of the
minimum transforming region of this oncogene must be
intact for transformation (35).
VOL. 54, 1985 119
120 PRYWES, FOULKES, AND BALTIMORE
+ PEFG PDPGpBpABdill.i +PNSGpB
v-abl 1 IT VN EKH VSNA.A YL SG
v-src 136 VA SD AE IRRE.S EL NP
v-f ps 809 PEVQKP9CQQ PS YS
SRD
- t.s. t.s.
30 ;..GLVESSSP UR. I .RYER. RINTA.l YVSE N167
.
G s AK YCL DFDNAK IYLY ITICRTQ$1838 ...
-.RS..Q YVL .W IIQ... AADN Y LDGDGLP PL LQS
PDPG-
P92td PNSG+ RIRA
92 ITYP PK TIYVSPN KW ITMK L YEV KYSLTVAVKTLKD235 D HLRANVCPT.K TQ A .K. RE L EV RVA0KTLKPG895 .RP TKSGIV VL........ LN V ER GEV S LR CRKPC
162 TrMiIE *E* F4A. M EI PNLVQLVC R PPYIIITE Y L L ECNRQEVSAV jLYR301 TEM ...FLQEAQVKKL E VQL SPIYI E S FGDlKYJqRLP V955 EP KAKQERT QC N VCKQ LVQGt DS K
.eP"RICMKKHI
RIRA PDPG RIRA
vw* V
229 EYL FHRDLAARNCLVGEHL VADFGLSRL TGDTYHA AK.FPIKWT367 IASGY G RiDL VENLVKVADFGL II NElYTAJRCAK1.IFPIKWTAPEEL1024 MENjCrHLANNT IF VFT
SRD
P92td pABS
298 Si K; ; ATiKLSLEIi R WN436 IYGT SDVWSFGIL[ TEFTKRVPYRDQCPPE.LHD
1094 EDVWSFGILLWEFSL QT I
AL
SRD SRD
367 PSFAEI iFETMFQESSISDEVEKELGKRGTRGGAGSMLQ-------
505 ERPtF1YLFK JQLLPACVLEVAE
1163 R GA LIAIRKRHR
FIG. 6. Position of mutations within the minimum transforming region. The deduced amino acid sequences of sections of v-abl (23; Lee
and Baltimore, unpublished data), v-src (30, 36), and v-fps (31) are shown. The amino acid position numbers from the beginning of v-abl and
v-src are indicated to the left of each line. The number for v-fps is from the beginning of the gag-fps fusion protein, P130fPs. The C-terminal
sequences of v-src and v-fps are shown, whereas the sequence of v-abl continues to amino acid number 1008 (in P160). The sequences were
aligned to maximize the homology throughout the src family of oncogene tyrosine kinases (Shiman and Baltimore, unpublished data). Similar
alignments for src andfps (31) and src and abl (23) have been published. Boxes indicate positions in the alignment where the same amino acid
is present in two or more of the sequences. The two asterisks indicate (i) the lysine residue whose position aligns with a lysine in the catalytic
subunit of the cAMP-dependent protein kinase which can be affinity labeled with an ATP analog and (ii) tyrosine number 416 of pp6O-src,
which is phosphorylated in vivo. The position of mutations and the fibroblast-transforming ability of plasmids containing each of the mutations(+ or -) are indicated. In v-abl, the mutations are indicated above each line in the appropriate positions. Solid arrows indicate deletions, and
the arrows indicate in which direction each sequence is deleted. Triangles indicate the position of linker insertions, with the amino acids that
are inserted as a consequence shown above each triangle. Both boundaries of the deletion in P92tdabl are shown. Deletions in v-src are
indicated by open-headed arrows in the appropriate position. Both ends of a deletion which causes a virus temperature sensitive for
transformation (5) are also indicated in this way. The positions and transforming abilities of linker insertions in v-fps are indicated below each
line. These result in the loss of one amino acid (Y) and the insertion of three amino acids (SRD). More details and references are given in the
text.
The various existing mutants help to define the region that the N-terminal deletion protein encoded by the pBl plasmid.
encodes the protein-tyrosine kinase activity of the oncogene For v-src, however, the N-terminal segment of the minimum
products. For v-abl, all nontransforming mutants were kin- transforming region is not required for kinase activity. This
ase negative, except for possible slight residual activity in is most dramatically shown by the ts deletion of amino acids
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34 to 85, which retains kinase activity at both temperatures
(5). For v-src, at least, the kinase activity appears to involve
mainly the C-terminal end of the minimum transforming
region. In fact, proteolysis of pp6Osrc produces a kinase-ac-
tive, C-terminal, 29,000-molecular-weight fragment (4, 18).
Also, deletion of amino acids in v-src after position 366
abolishes transforming and kinase activities (see Fig. 6; V.
Wilkerson and J. T. Parsons, personal communication), as
do point mutants at amino acids 292 to 296 (6, 21).
A final suggestion that the C-terminal portion of the
minimum transforming region is the kinase domain comes
from the properties of antibodies made to different regions of
the v-src and v-abl proteins. For v-src, an antipeptide serum
against amino acids 360 to 374 neutralizes kinase activity
(10). For v-abl, antisera to amino acids 138 to 148 and 232 to
355 block kinase activity (16).
These comparisons lead to similar pictures for the v-abl
and v-src minimum transforming regions, except that the
N-terminal sequence may be more important to v-abl than to
v-src. A further similarity is that both oncogenes have a
requirement for N-terminal amino acids which are not part
of the minimum transforming region (9; R. Prywes and D.
Baltimore, unpublished data); in A-MuLV they are encoded
by gag, and in v-src they are derived from c-src. Because the
N-terminal glycines of both proteins contain covalently
bound myristate (29; A. Schultz, personal communication),
the requirement for the N-terminal sequence might be for
specifying myristylation, which could then play a role in the
membrane-binding of these proteins.
In spite of the great similarities between v-abl and v-src,
there are crucial biological differences between them. When
placed into a common murine retroviral context, v-abl
efficiently transforms lymphoid cells, as well as established
fibroblasts, whereas v-src affects only fibroblasts and not
lymphoid cells (B. Mathey-Prevot and D. Baltimore, unpub-
lished data). Also, the substrate specificity of the purified
v-abl-encoded kinase is different from that of the v-src-en-
coded kinase (J. G. Foulkes and D. Baltimore, unpublished
data [discussed by J. G. Foulkes, B. Mathey-Prevot, B. C.
Guild, R. Prywes, and D. Baltimore in J. Feramisco, B.
Ozanne, and C. Stiles, ed., Growth factors and transforma-
tion]). The sequence differences between the two minimum
transforming regions therefore cause significant differences
in the behavior of the two oncogenes, although we cannot
tell at present what residues are responsible for encoding
abl-specific properties. Perhaps the important difference lies
in the N-terminal segment of the minimum transforming
region.
ACKNOWLEDGMENTS
This work was supported by Public Health Service grant CA26717
from the National Cancer Institute.
LITERATURE CITED
1. Abelson, H. T., and L. S. Rabstein. 1970. Lymphosarcoma:
virus-induced thymic-independent disease in mice. Cancer Res.
30:2213-2222.
2. Barker, W. C., and M. 0. Dayhoff. 1982. Viral src gene products
are related to the catalytic chain of mammalian cAMP-depend-
ent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 79:2836-2840.
3. Bishop, J. M. 1983. Cellular oncogenes and retroviruses. Annu.
Rev. Biochem. 52:301-354.
4. Brugge, J. S., and D. Darrow. 1984. Analysis of the catalytic
domain of phosphotransferase activity of two avian sarcoma
virus-transforming proteins. J. Biol. Chem. 259:4550-4557.
5. Bryant, D., and J. T. Parsons. 1982. Site-directed mutagenesis
of the src gene of Rous sarcoma virus: construction and
characterization of a deletion mutant temperature sensitive for
transformation. J. Virol. 44:683-691.
6. Bryant, D., and J. T. Parsons. 1983. Site-directed point mutation
in the src gene of Rous sarcoma virus results in an inactive src
gene product. J. Virol. 45:1211-1216.
7. Cheng, Y. E., and L. B. Chen. 1981. Detection of phosphotyro-
sine-containing 34,000-dalton protein in the framework of cells
transformed with Rous sarcoma virus. Proc. Natl. Acad. Sci.
U.S.A. 78:2388-2392.
8. Cooper, J. A., and T. Hunter. 1981. Changes in protein phos-
phorylation in Rous sarcoma virus-transformed chicken embryo
cells. Mol. Cell. Biol. 1:165-178.
9. Cross, F. R., E. A. Garber, D. Pellman, and H. Hanafusa. 1984.
A short sequence in the p60src N terminus is required for p6osrc
myristylation and membrane association, and for cell transfor-
mation. Mol. Cell. Biol. 4:1834-1842.
10. Gentry, L. E., L. R. Rohrschneider, J. E. Casnellie, and E. G.
Krebs. 1983. Antibodies to a defined region of pp6fsrc neutralize
the tyrosine-specific kinase activity. J. Biol. Chem. 258:
11219-11228.
11. Goff, S. P., E. Gilboa, 0. N. Witte, and D. Baltimore. 1980.
Structure of the Abelson murine leukemia virus genome and the
homologous cellular gene: studies with cloned DNA. Cell
22:777-7858.
12. Goff, S. P., C. J. Tabin, J. Y.-J. Wang, R. Weinberg, and D.
Baltimore. 1982. Transfection of fibroblasts by cloned Abelson
murine leukemia virus DNA and recovery of transmissible virus
by recombination with helper virus. J. Virol. 41:271-285.
13. Hunter, T., and B. M. Sefton. 1981. Protein kinases and viral
transformation, p. 337-370. In P. Cohen and S. van Heyningen,
(ed.), Molecular aspects of cellular regulation. Elsevier/North-
Holland Publishing Co., New York.
14. Hwang, L.-H. S., and E. Gilboa. 1984. Expression of genes
introduced into cells by retroviral infection is more efficient than
that of genes introduced into cells by DNA transfection. J.
Virol. 50:417-424.
15. Ish-Horowicz, D., and J. F. Burke. 1981. Rapid and efficient
cosmid vector cloning. Nucleic Acids Res. 9:2989-2998.
16. Knopka, J. B., R. L. Davis, S. M. Watanabe, A. S. Ponticelli, L.
Schiff-Maker, N. Rosenberg, and 0. N. Witte. 1984. Only site-
directed antibodies reactive with the highly conserved src-ho-
mologous region of the v-abl protein neutralize kinase activity.
J. Virol. 51:223-232.
17. Latt, S. A., S. P. Goff, C. J. Tabin, M. Paskind, J. Y.-J. Wang,
and D. Baltimore. 1983. Cloning and analysis of reverse tran-
script P160 genomes of Abelson murine leukemia virus. J. Virol.
45:1195-1199.
18. Levinson, A. D., S. A. Courneidge, and J. M. Bishop. 1981.
Structural and functional domains of the Rous sarcoma virus
transforming protein (pp60sr). Proc. Natl. Acad. Sci. U.S.A.
78:1624-1628.
19. Maxam, A. M., and W. Gilbert. 1977. A new method for
sequencing DNA. Proc. Natl. Acad. Sci. U.S.A. 74:560-564.
20. Mulligan, R. C. 1983. Construction of highly transmissible
mammalian cloning vehicles derived from murine retroviruses,
p. 155-173. In M. Inouye, (ed.), Experimental manipulation of
gene expression. Academic Press, Inc., New York.
21. Parsons, J. T., D. Bryant, V. Wilkerson, G. Gilmartin, and S. J.
Parsons. 1984. Site-directed mutagenesis of Rous sarcoma virus
pp6Osrc: identification of functional domains required for trans-
formation, p. 37-42. In G. F. Vande Woude, A. J. Levine, W.
Topp, and J. D. Watson (ed.), Cancer cells. Oncogenes and viral
genes. Cold Spring Harbor Laboratory, Cold Spring Harbor,
N.Y.
22. Prywes, R., J. G. Foulkes, N. Rosenberg, and D. Baltimore.
1983. Sequences of the A-MuLV protein needed for fibroblast
and lymphoid cell transformation. Cell 34:569-579.
22a.Prywes, R., J. Hoag, N. Rosenberg, and D. Baltimore. 1985.
Protein stabilization explains the gag requirement for transfor-
mation of lymphoid cells by Abelson murine leukemia virus. J.
Virol. 54:123-132.
23. Reddy, E. P., M. J. Smith, and A. Srinivasan. 1983. Nucleotide
sequence of Abelson murine leukemia virus genome: structural
121VOL. 54, 1985
122 PRYWES, FOULKES, AND BALTIMORE
similarity of its transforming gene product to other onc gene
products with tyrosine-specific kinase activity. Proc. Natl.
Acad. Sci. U.S.A. 80:3623-3627.
24. Reynolds, F. H., T. L. S. Sacks, D. N. Deobaghar, and J. P.
Stephenson. 1978. Cells non-productively transformed by Abel-
son murine leukemia virus express a high molecular weight
polyprotein containing structural and non-structural compo-
nents. Proc. Natl. Acad. Sci. U.S.A. 75:3974-3978.
25. Rosenberg, N., and D. IBaltimore. 1976. A quantitative assay for
transformation of bone marrow cells by Abelson murine leuke-
mia virus. J. Exp. Med. 143:1453-1463.
26. Rosenberg, N., D. Baltimore, and C. D. Scher. 1975. In vitro
transformation of lymphoid cells by Abelson murine leukemia
virus. Proc. Natl. Acad. Sci. U.S.A. 72:1932-1936.
27. Rosenberg, N., D. R. Clark, and 0. N. Witte. 1980. Abelson
murine leukemia virus mutants deficient in kinase activity and
lymphoid cell transformation. J. Virol. 36:766-774.
28. Scher, C. D., and R. Siegler. 1975. Direct transformation of 3T3
cells by Abelson murine leukemnia virus. Nature (London)
253:729-731.
29. Schultz, A., and S. Oroszlan. 1984. Myristylation of gag-onc
fusion proteins in mammalian transforming retroviruses. Virol-
ogy 133:431-437.
30. Schwartz, D. E., R. Tizard, and W. Gilbert. 1983. Nucleotide
sequence of Rous sarcoma virus. Cell 32:853-869.
31. Shibuya, M., and H. Hanafusa. 1982. Nucleotide sequence of
Fujinami sarcoma virus: evolutionary relationship of its trans-
forming gene with transforming genes of other sarcoma viruses.
Cell 30:787-795.
32. Shields, A., S. P. Goff, M. Paskind. G. Otto, and D. Baltimore.
1979. Structure of the Abelson murine leukemia virus genome.
Cell 18:955-962.
33. Shoj., S., D. C. Parmelee, R. D. Wade, S. Kumar, L. H.
Ericsson, K. A. Walsh, H. Neurath, G. L. Long, J. G. Demaille,
E. H. Fischer, and K. Titani. 1981. Complete amino acid se-
quence of the catalytic subunit of bovine cardiac muscle cyclic
AMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A.
78:848-851.
34. Srinivasan, A., C. Y. Dunn, Y. Yuasa, S. G. Devare, E. P.
Reddy, and S. A. Aaronson. 1982. Abelson murine leukemia
virus: structural requirements for transforming gene function.
Proc. Natl. Acad. Sci. U.S.A. 79:5508-5512.
35. Stone, J. C., T. Atkinson; M. Smith, and T. Pawson. 1984.
Identification of functional regions in the transforming protein of
Fujinami sarcoma virus by in-phase insertion mutagenesis. Cell
37:549-558.
36. Takeya, T., R. Feldman, and H. Hanafusa. 1982. DNA sequence
of the viral and cellular src gene of chickens. I. The complete
nucleotide sequence of an EcoRI fragment of recovered avian
sarcoma virus which codes for gp37 and pp6Osr. J. Virol.
44:1-11.
37. Vogelstein, B., and D. Gillespie. 1979. Preparative and analytical
purification of DNA from agarose. Proc. Natl. Acad. Sci.
U.S.A. 76:615-619.
38. Wang, J. Y.-J., F. Ledley, S. Goff, R. Lee, Y. Groner, and D.
Baltimore. 1984. The mouse c-abl locus: molecular cloning and
characterization. Cell 36:349-356.
39. Wang, J. Y.-J., C. Queen, and D. Baltimore. 1982. Expression of
an Abelson murine leukemia virus encoded protein in Esche-
richia coli caused extensive phosphorylation of tyrosine resi-
dues. J. Biol. Chem. 257:13181-13184.
40. Wigler, M., R. Sweet, G. K. Sim, B. Wold, A. Pellicer, E. Lacy,
T. Maniatis, S. Silverstein, and R. Axel. 1979. Transfornmation of
mammalian cells with genes from procaryotes and eukaryotes.
Cell 16:777-785.
41. Witte, 0. N., A. Dasgupta, and D. Baltimore. 1980. Abelson
murine leukemia virus protein is phosphorylated in vitro to form
phosphotyrosine. Nature (London) 283:826-831.
42. Witte, 0. N., S. P. Goff, N. Rosenberg, and D. Baltimore. 1980.
A transformation defective mutant of Abelson murine leukemia
virus lacks protein kinase activity. Proc. NatI. Acad. Sci.
U.S.A. 77:4993-4997.
43. Witte, 0. N., N. Rosenberg, and D. Baltimore. 1979. Preparation
of syngeneic tumor regressor serum reactive with the unique
determinants of the Abelson murine leukemia virus-encoded
P120 protein at the cell surface. J. Virol. 31:776-784.
44. Witte, 0. N., N. Rosenberg, M. Paskind, A. Shields, and D.
Baltimore. 1978. Identification of an Abelson murine leukemia
virus encoded protein present in transformed fibroblast and
lymphoid cells. Proc. Natl. Acad. Sci. U.S.A. 75:2488-2492.
J. VIROL.
